Failure in HiRes Ultra Series Recall Devices Does Not Necessarily Lead to Decrement in Performance.

IF 1.9 3区 医学 Q3 CLINICAL NEUROLOGY
Erin Harvey, Muhammad Khokhar, Michael S Harris, Jazzmyne Adams, David R Friedland
{"title":"Failure in HiRes Ultra Series Recall Devices Does Not Necessarily Lead to Decrement in Performance.","authors":"Erin Harvey, Muhammad Khokhar, Michael S Harris, Jazzmyne Adams, David R Friedland","doi":"10.1097/MAO.0000000000004212","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To understand the impact on speech perception for patients experiencing Advanced Bionics V1 series Ultra and Ultra 3D cochlear implant failure.</p><p><strong>Study design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Tertiary academic center.</p><p><strong>Patients: </strong>Adult patients implanted with V1 series devices.</p><p><strong>Interventions: </strong>Device integrity and speech perception testing.</p><p><strong>Main outcome measures: </strong>consonant-nucleus-consonant and AzBio in quiet speech recognition scores.</p><p><strong>Results: </strong>At our institution, 116 V1 series cochlear implants were placed in 114 patients. Thirteen devices in prelingual patients were excluded, leaving 103 (89%) for final analysis. Forty-eight (46.6%) devices were considered as failed using the company provided EFI analysis tool. There were 36 (65.5%) of the remaining 55 devices that consistently tested within normal range; the remainder lost to follow-up with unknown status. Among the 48 device failures, 29 were revised and 19 patients were not revised. Among those not revised, 11 self-opted for observation (57.9%). Observed patients, despite impedance changes meeting failure criteria, had no subjective or objective changes in speech perception. Sentence testing scores for failure patients who elected observation (82.9 ± 11.4%) were significantly higher at failure compared with those opting for revision (55 ± 22.8%, p = 0.006). For those undergoing revision surgery, significant improvement in post-activation scores was noted as compared with time of failure with a mean improvement of 12.9% (p = 0.002, n = 24) for consonant-nucleus-consonant word scores and 17.2% (p = 0.001, n = 19) for AzBio in quiet scores.</p><p><strong>Conclusions: </strong>Proactive monitoring using EFI identifies a higher rate of Ultra Series V1 device failure than previously reported. However, about 20% of these patients may not have subjective change in hearing or objective decline in test scores and could be observed. Should performance worsen, reimplantation provides significant improvement in speech recognition.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otology & Neurotology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MAO.0000000000004212","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To understand the impact on speech perception for patients experiencing Advanced Bionics V1 series Ultra and Ultra 3D cochlear implant failure.

Study design: Retrospective cohort study.

Setting: Tertiary academic center.

Patients: Adult patients implanted with V1 series devices.

Interventions: Device integrity and speech perception testing.

Main outcome measures: consonant-nucleus-consonant and AzBio in quiet speech recognition scores.

Results: At our institution, 116 V1 series cochlear implants were placed in 114 patients. Thirteen devices in prelingual patients were excluded, leaving 103 (89%) for final analysis. Forty-eight (46.6%) devices were considered as failed using the company provided EFI analysis tool. There were 36 (65.5%) of the remaining 55 devices that consistently tested within normal range; the remainder lost to follow-up with unknown status. Among the 48 device failures, 29 were revised and 19 patients were not revised. Among those not revised, 11 self-opted for observation (57.9%). Observed patients, despite impedance changes meeting failure criteria, had no subjective or objective changes in speech perception. Sentence testing scores for failure patients who elected observation (82.9 ± 11.4%) were significantly higher at failure compared with those opting for revision (55 ± 22.8%, p = 0.006). For those undergoing revision surgery, significant improvement in post-activation scores was noted as compared with time of failure with a mean improvement of 12.9% (p = 0.002, n = 24) for consonant-nucleus-consonant word scores and 17.2% (p = 0.001, n = 19) for AzBio in quiet scores.

Conclusions: Proactive monitoring using EFI identifies a higher rate of Ultra Series V1 device failure than previously reported. However, about 20% of these patients may not have subjective change in hearing or objective decline in test scores and could be observed. Should performance worsen, reimplantation provides significant improvement in speech recognition.

HiRes Ultra 系列召回设备出现故障并不一定会导致性能下降。
目的:了解先进仿生公司 V1 系列 Ultra 和 Ultra 3D 人工耳蜗故障对患者语言感知的影响:了解 Advanced Bionics V1 系列 Ultra 和 Ultra 3D 人工耳蜗失败对患者言语感知的影响:研究设计:回顾性队列研究:三级学术中心:患者:植入 V1 系列设备的成年患者:主要结果测量:辅音-核-共鸣和AzBio安静语音识别评分:在本机构,114 名患者植入了 116 个 V1 系列人工耳蜗。其中有 13 名语前患者的设备被排除在外,最终分析结果为 103 人(89%)。使用公司提供的 EFI 分析工具,48 台(46.6%)设备被认为是失败的。在剩余的 55 台设备中,有 36 台(65.5%)的测试结果一直在正常范围内;其余设备因状态不明而失去随访。在 48 例装置故障中,29 例进行了修正,19 例患者未进行修正。在未修改的患者中,有 11 人自行选择了观察(57.9%)。接受观察的患者尽管阻抗变化符合故障标准,但在言语感知方面没有主观或客观的变化。选择观察的失败患者的句子测试得分(82.9 ± 11.4%)明显高于选择修正的患者(55 ± 22.8%,P = 0.006)。与失败时相比,接受复健手术的患者在激活后的评分有明显改善,辅音-核-谐音词评分平均提高了 12.9% (p = 0.002, n = 24),AzBio in quiet 评分平均提高了 17.2% (p = 0.001, n = 19):结论:使用 EFI 进行前瞻性监测发现的 Ultra Series V1 设备故障率高于之前的报告。然而,这些患者中约有 20% 的人可能没有主观听力变化或客观测试评分下降,因此可以对其进行观察。如果性能恶化,重新植入可显著提高语音识别能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Otology & Neurotology
Otology & Neurotology 医学-耳鼻喉科学
CiteScore
3.80
自引率
14.30%
发文量
509
审稿时长
3-6 weeks
期刊介绍: ​​​​​Otology & Neurotology publishes original articles relating to both clinical and basic science aspects of otology, neurotology, and cranial base surgery. As the foremost journal in its field, it has become the favored place for publishing the best of new science relating to the human ear and its diseases. The broadly international character of its contributing authors, editorial board, and readership provides the Journal its decidedly global perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信